Current investments

Receive information about upcoming investment opportunities

Sign up below to get information about upcoming investment opportunities and investor lunch meetings with the companies’ management.

Completed investments

Image showing a nanomolecular structure.

Synartro: 2

Synartro is developing a unique treatment for knee osteoarthritis by combining two proven drugs, which will offer an effective and safe alternative to today’s treatments.

Read more
An enlarged image of nerve cells with nerve fibers, so-called axons.

PharmNovo

PharmNovo develops drugs for chronic pain based on a new type of selective delta opioids. The main candidate PN6047 shows promising results on effective pain relief without negative side effects.

Read more
The Sciety syndicate invests in Synartro Synartro is developing a novel therapy for knee osteoarthritis.

Synartro: 1

Osteoarthritis affects more than 240 million people globally. Synartro is developing a novel therapy for knee osteoarthritis with fewer side effects and improved efficacy to meet the needs of the ageing population.

Read more

Cavis Technologies

Cavis Technologies has developed a combined guidewire/catheter, Wirecath®, for diagnosis of people with coronary heart disease. Wirecath® is expected to provide important clinical benefits.

Read more

Exits

Liv Diagnostics

Tumor cell proliferation causes 90% of all cancer deaths. Liv Diagnostics is developing new technology to measure the spreading capacity of tumor cells and provide predictive information on the risk of metastasis.

Read more